Amicus Therapeut Stock Price, News & Analysis

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is described as a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. The company states that it is committed to advancing and expanding a pipeline of first- or best-in-class medicines for rare diseases, with a particular emphasis on serious, genetically defined conditions.

According to company disclosures, Amicus has developed commercial therapies for Fabry disease and late-onset Pompe disease and is active in clinical and late-stage development programs in rare disease. Its work is positioned within the pharmaceutical preparation manufacturing industry, where it concentrates on therapies for small, well-defined patient populations.

Core focus and rare disease portfolio

Amicus highlights two marketed products for lysosomal storage disorders. Galafold (migalastat) is described as an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body's own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Company materials note that Galafold is approved in more than 40 countries, including the U.S., European Union, United Kingdom and Japan.

Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) is described as a two-component therapy for adults with late-onset Pompe disease (LOPD) who meet specific clinical criteria. Pombiliti is a recombinant human GAA enzyme enriched with bis-M6P (Mannose 6-Phosphate) and designed for high-affinity uptake through the M6P receptor, while Opfolda is an oral enzyme stabilizer intended to reduce loss of enzyme activity in the blood. The combination is indicated in the U.S. for adult LOPD patients weighing at least 40 kg who are not improving on their current enzyme replacement therapy.

Clinical development and pipeline elements

Beyond its marketed products, Amicus reports involvement in late-stage clinical research. Company communications describe a Phase 3 program known as PROPEL and its open-label extension for cipaglucosidase alfa-atga plus miglustat in adults with late-onset Pompe disease. Analyses from these studies have examined endpoints such as six-minute walk distance, forced vital capacity, muscle strength, biomarkers and patient-reported outcomes in enzyme replacement therapy (ERT)-experienced and ERT-naïve patients.

Amicus also reports U.S. rights to DMX-200, described as a potential first-in-class investigational small molecule for the treatment of focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease. The Phase 3 ACTION3 study of DMX-200 is being conducted by Dimerix, with Amicus citing a U.S. licensing agreement for commercialization rights.

Business model and segment focus

Public descriptions characterize Amicus as operating through a single segment focused on the discovery, development and commercialization of therapies to treat a range of devastating rare and orphan diseases. Revenue is associated with its rare disease medicines, including Galafold for Fabry disease and Pombiliti + Opfolda for late-onset Pompe disease, as reflected in periodic financial updates that break out net product revenues for these therapies.

The company repeatedly emphasizes a patient-centric approach, describing itself as "patient-dedicated" and highlighting collaboration with rare disease communities, including patients, families, physicians and advocacy groups, in its communications. This focus is positioned as central to its research priorities and commercialization strategy in Fabry disease, Pompe disease and other rare conditions.

Geographic and regulatory footprint

Amicus is associated with operations in Princeton, New Jersey, as indicated in its SEC filings, and describes itself as a global biotechnology company. Its products have obtained regulatory approvals in multiple major markets. Company statements note that Galafold is approved in more than 40 countries worldwide, including the U.S., EU, U.K. and Japan. Pombiliti + Opfolda is reported as approved in the U.S., European Union, United Kingdom, Canada, Australia, Switzerland and Japan for specified adult LOPD patient populations.

Regulatory milestones for Pombiliti + Opfolda include approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adult late-onset Pompe disease. The company cites data from the Phase 3 PROPEL study as the basis for this decision, noting that PROPEL enrolled both ERT-naïve and ERT-experienced participants.

Corporate developments and pending acquisition

On December 19, 2025, BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced that they had entered into a definitive agreement under which BioMarin would acquire Amicus for $14.50 per share in an all-cash transaction valued at approximately $4.8 billion. The announcement states that the Boards of Directors of both companies unanimously approved the agreement and that the Amicus Board recommended that stockholders vote to adopt it. The transaction is described as expected to close in the second quarter of 2026, subject to regulatory clearances, approval by Amicus stockholders and other customary closing conditions.

According to the joint announcement, the proposed acquisition would add Galafold and Pombiliti + Opfolda to BioMarin's portfolio of medicines targeting lysosomal storage disorders and provide BioMarin with U.S. rights to DMX-200. The companies state that the combination is intended to expand access to Galafold and Pombiliti + Opfolda across BioMarin's global commercial footprint and to accelerate BioMarin's revenue growth.

Fabry disease and Galafold

Fabry disease is described in company materials as a condition in which certain adults have amenable GLA gene variants that can be targeted by pharmacological chaperones. Galafold (migalastat) 123 mg capsules is indicated in the U.S. for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable GLA variant based on in vitro assay data. The indication was granted under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate, with continued approval potentially contingent on verification and description of clinical benefit in confirmatory trials.

Safety information disclosed for Galafold notes that the most common adverse reactions (≥10%) include headache, nasopharyngitis, urinary tract infection, nausea and pyrexia. The company also states that Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis and that safety and effectiveness have not been established in pediatric patients.

Late-onset Pompe disease and Pombiliti + Opfolda

Late-onset Pompe disease is described as an inherited lysosomal disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA), leading to accumulation of glycogen in cells and progressive muscle weakness, including muscles involved in breathing. Pombiliti in combination with Opfolda is indicated in the U.S. for adult patients with late-onset Pompe disease weighing at least 40 kg who are not improving on their current enzyme replacement therapy.

Company safety information for Pombiliti + Opfolda highlights risks such as hypersensitivity reactions including anaphylaxis, infusion-associated reactions and risk of acute cardiorespiratory failure in susceptible patients. The combination is contraindicated in pregnancy and carries warnings regarding embryo-fetal toxicity, with recommendations for effective contraception during treatment and for a period after the last dose. Common adverse reactions (≥5%) include headache, diarrhea, fatigue, nausea, abdominal pain and pyrexia.

Research, data and publications

Amicus communications describe multiple analyses from the PROPEL study and its open-label extension, including four-year data on muscle function, muscle strength and biomarker endpoints in adults with late-onset Pompe disease treated with cipaglucosidase alfa-atga plus miglustat. The company reports that, in ERT-experienced patients, measures of muscle function, muscle strength and biomarkers improved and/or were sustained out to 208 weeks, with no new safety signals identified in the open-label extension.

A post-hoc analysis of the ERT-experienced cohort from PROPEL, published in the journal Muscle and Nerve, is summarized as showing that patients who switched from alglucosidase alfa to cipaglucosidase alfa-atga plus miglustat experienced improvement or stability across many outcomes, whereas those remaining on alglucosidase alfa plus placebo generally showed stability or worsening on several measures. These analyses are presented by the company as adding to the evidence base for Pombiliti + Opfolda in late-onset Pompe disease.

Position within the rare disease biotechnology sector

Within the broader pharmaceutical preparation manufacturing and biotechnology landscape, Amicus positions itself as focused on rare diseases, particularly Fabry disease, late-onset Pompe disease and focal segmental glomerulosclerosis. Its disclosures emphasize the development and commercialization of medicines for small, underserved patient populations and the use of clinical and real-world data to characterize treatment effects over time.

Investors and analysts reviewing FOLD stock typically consider the performance of Galafold and Pombiliti + Opfolda, progress in clinical programs such as DMX-200, regulatory and reimbursement milestones in key markets, and the status of the proposed acquisition by BioMarin, as reflected in company press releases and SEC filings.